HK1064948A1 - Use of an adenosine a3 receptor agonist for inhibition of viral replication - Google Patents

Use of an adenosine a3 receptor agonist for inhibition of viral replication

Info

Publication number
HK1064948A1
HK1064948A1 HK04107798A HK04107798A HK1064948A1 HK 1064948 A1 HK1064948 A1 HK 1064948A1 HK 04107798 A HK04107798 A HK 04107798A HK 04107798 A HK04107798 A HK 04107798A HK 1064948 A1 HK1064948 A1 HK 1064948A1
Authority
HK
Hong Kong
Prior art keywords
adenosine
viral replication
cells
receptor agonist
inhibition
Prior art date
Application number
HK04107798A
Other languages
English (en)
Inventor
Pnina Fishman
Kamel Khalili
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of HK1064948A1 publication Critical patent/HK1064948A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04107798A 2001-01-16 2004-10-11 Use of an adenosine a3 receptor agonist for inhibition of viral replication HK1064948A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26165901P 2001-01-16 2001-01-16
PCT/IL2002/000028 WO2002055085A2 (fr) 2001-01-16 2002-01-13 Utilisation d'un agoniste du recepteur a3 d'adenosine pour l'inhibition de replication virale

Publications (1)

Publication Number Publication Date
HK1064948A1 true HK1064948A1 (en) 2005-02-08

Family

ID=22994269

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107798A HK1064948A1 (en) 2001-01-16 2004-10-11 Use of an adenosine a3 receptor agonist for inhibition of viral replication

Country Status (12)

Country Link
US (1) US7589075B2 (fr)
EP (1) EP1365776B1 (fr)
JP (1) JP4012070B2 (fr)
CN (1) CN1259056C (fr)
AT (1) ATE292973T1 (fr)
AU (1) AU2002219497B2 (fr)
BR (1) BR0206492A (fr)
CA (1) CA2434906C (fr)
DE (1) DE60203702T2 (fr)
HK (1) HK1064948A1 (fr)
IL (1) IL156704A0 (fr)
WO (1) WO2002055085A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP2221307A1 (fr) 2004-05-26 2010-08-25 Inotek Pharmaceuticals Corporation Derivés de purines agonistes du récepteur adénosine A1 et leur utilisation
MX2007003271A (es) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20060194756A1 (en) * 2004-11-22 2006-08-31 Borea Pier A Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2627319A1 (fr) 2005-11-30 2007-06-07 Prakash Jagtap Derives de purine et leurs procedes d'utilisation
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1889846A1 (fr) 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
EP1903044A1 (fr) 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
CA2669108A1 (fr) * 2006-11-10 2008-05-15 Novartis Ag Derives de monoacetate de cyclopentene diol
PT2137202T (pt) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
EP2227234B1 (fr) 2007-10-15 2014-05-07 Can-Fite Biopharma Ltd. Procédé pour induire une prolifération d'hépatocytes et ses utilisations
WO2011010306A1 (fr) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. Ligands du récepteur a3 de l’adénosine modulant la pigmentation
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
CN104114568B (zh) 2011-12-22 2017-09-01 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP2806878A1 (fr) * 2012-01-23 2014-12-03 Can-Fite Biopharma Ltd. Traitement de troubles hépatiques
SG11201403979TA (en) 2012-01-26 2014-08-28 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014024195A1 (fr) * 2012-08-09 2014-02-13 Can-Fite Biopharma Ltd. Ligands du récepteur a3 de l'adénosine pour l'utilisation dans le traitement d'un dysfonctionnement sexuel
EP2968389A4 (fr) 2013-03-15 2016-08-24 Inotek Pharmaceuticals Corp Formulations ophtalmiques
IL242723B (en) * 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
WO2017185061A1 (fr) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Composés et procédés pour traiter des états neurologiques et cardiovasculaires
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
BR112021005290A2 (pt) 2018-09-26 2021-06-22 Astrocyte Pharmaceuticals, Inc. compostos polimórficos e usos dos mesmos
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
EP0708781B1 (fr) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services Agonistes du recepteur de l'adenosine a 3
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs

Also Published As

Publication number Publication date
CN1489470A (zh) 2004-04-14
DE60203702T2 (de) 2006-03-02
CA2434906C (fr) 2008-08-19
DE60203702D1 (de) 2005-05-19
WO2002055085A2 (fr) 2002-07-18
CA2434906A1 (fr) 2002-07-18
US7589075B2 (en) 2009-09-15
IL156704A0 (en) 2004-01-04
JP2004517864A (ja) 2004-06-17
US20040106572A1 (en) 2004-06-03
EP1365776B1 (fr) 2005-04-13
WO2002055085A3 (fr) 2002-12-19
EP1365776A2 (fr) 2003-12-03
CN1259056C (zh) 2006-06-14
AU2002219497B2 (en) 2004-08-26
BR0206492A (pt) 2004-02-10
ATE292973T1 (de) 2005-04-15
JP4012070B2 (ja) 2007-11-21

Similar Documents

Publication Publication Date Title
IL156704A0 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP1476138A4 (fr) Formulations a liberation modifiee d'au moins une forme de tramadol
MXPA02010971A (es) Poblaciones de espermatozoides que portan cromosoma x y que porta cromosoma y de alta pureza.
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
HK1091130A1 (en) Pharmaceuical compositions for hepatitis c viral protease inhibitors
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
HK1029520A1 (en) Method for preventing hiv-1 infection of cd4+ cells
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2004085682A3 (fr) Utilisation de substances actives pour la prevention ou le traitement de maladies virales, et systeme de test pour la recherche de telles substances actives
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
EP1201765A3 (fr) Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
EP0695184A4 (fr) Inhibiteurs de la protease du vih
ZA991029B (en) Composition and methods for treatment of hiv infections.
ES2156444T3 (es) Nuevos compuestos.
MY140724A (en) Novel arylethene-sulfonamides
WO1998004717A3 (fr) Peptides derives de la proteine kinase dependant de l'arn double brin, utilises pour favoriser la proliferation de cellules et de tissus de maniere controlee
AU3777197A (en) Cyclosporin formulation
AU2003255611A1 (en) Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase
EP0930069A3 (fr) Compositions destinees a diminuer la formation de cicatrices
WO2001055176A3 (fr) Procedes d'inhibition de la proliferation des cellules du muscle lisse
MXPA04003124A (es) Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno.
AU2001250722A1 (en) Medicament for the treatment of diseases caused by parasitic protozoa

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220112